Allergy Therapeutics plc has disclosed a public dealing disclosure by Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. The disclosure includes key information such as the name of the exempt principal trader, the name of the offeror/offeree (Allergy Therapeutics plc), and the date of dealing undertaken (21 Sep 2023).

The disclosure also provides information on the dealings by the exempt principal trader, including purchases and sales of the relevant securities of Allergy Therapeutics plc. In this case, the exempt principal trader made sales of 116,500 securities at a price per unit of 0.02564.

The disclosure does not include any cash-settled derivative transactions or stock-settled derivative transactions. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing.

The contact information for the disclosure is provided, including the name of Freddie Wooding and the telephone number +44 (0)20 7886 2969.

Overall, the disclosure provides information on the dealings of Panmure Gordon (UK) Limited as an exempt principal trader with recognized intermediary status in relation to Allergy Therapeutics plc.